Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

INTERVIEW: The Biosimilar Brain - Celltrion’s Dr. Stanley Hong

This article was originally published in PharmAsia News

Executive Summary

South Korean firm Celltrion Healthcare is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar, Remsima (infliximab), which was rolled out across Europe earlier this year and is currently under review by the US FDA. Celltrion CEO talks about the impact the product will have and how will the broader biosimilar sector will develop.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register